Business Update

Advancis Pharmaceutical provides update on additional Keflex products

Published in Medical Letter on the CDC and FDA, May 24th, 2006

Advancis Pharmaceutical Corp. (AVNC), a pharmaceutical company focused on developing and commercializing novel anti-infective products, announced that the U.S. Food and Drug Administration (FDA) has informed the company that its review of the supplemental New Drug Application for additional Keflex (cephalexin capsules, USP) products is still ongoing.

"We were notified yesterday that the agency has not yet completed their review of our application," said Edward M. Rudnic, PhD, president and CEO of Advancis. "However, we were informed that the FDA will be working to complete their review and we look forward to receiving the FDA's final action in the near future. We draw...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2006-05-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry